Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic
- 26 December 2021
- journal article
- review article
- Published by Taylor & Francis in Critical Reviews in Biotechnology
- Vol. 42 (7) , 1079-1098
Abstract
Chimeric antigen receptor T cell (CAR-T) therapy has been recognized as one of the most prosperous treatment options against certain blood-based malignancies. However, the same clinical and commercial success have been out of range in the case of solid tumors. The main contributing factor in this regard is the hostile environment the tumor cells impose that results in the exhaustion of immune effector cells alongside the abrogation of their infiltration capacity. The discovery of the underlying mechanisms and the development of reliable counterstrategies to overcome the inaccessibility of CAR-Ts to their target cells might correlate with encouraging clinical outcomes in advanced solid tumors. Here, we highlight the successive physical and metabolic barriers that systemically administered CAR-Ts face on their journey toward their target cells. Moreover, we propose meticulously-devised countertactics and combination therapies that can be applied to maximize the therapeutic benefits of CAR-T therapies against solid tumors.Keywords
This publication has 100 references indexed in Scilit:
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumorsJournal of Clinical Investigation, 2012
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody ReceptorClinical Cancer Research, 2011
- Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivityin vitroandin vivoin colon cancer cell line modelsInternational Journal of Cancer, 2011
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2bJournal of Immunotherapy, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Macrophage-derived IL-1β stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3Oncogene, 2009
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatmentBlood, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancerCancer Immunology, Immunotherapy, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006